Zenosense Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
SG&A Expense
447.90
610.40
146.50
134.40
158.90
EBIT
447.90
610.40
146.50
134.40
158.90
Interest Expense
0.10
0.30
3.70
71.80
252.40
Pretax Income
448.00
610.70
150.20
249.40
566.30
Consolidated Net Income
448.00
610.70
150.20
249.40
566.30
Net Income
448.00
610.70
150.20
249.40
566.30
Net Income After Extraordinaries
448.00
610.70
150.20
249.40
566.30
Net Income Available to Common
448.00
610.70
150.20
249.40
566.30
EPS (Basic)
0.04
0.09
0.02
0.02
0.03
Basic Shares Outstanding
12,414.20
6,975.10
7,087.90
12,563.80
21,141.90
EPS (Diluted)
0.04
0.09
0.02
0.02
0.03
Diluted Shares Outstanding
12,414.20
6,975.10
7,087.90
12,563.80
21,141.90
EBITDA
447.90
610.40
146.50
134.40
158.90
Equity in Affiliates (Pretax)
-
-
-
43.20
155.00

About Zenosense

View Profile
Address
Avenida Cortes Valencianas 58
Valencia Valencia 46015
Spain
Employees -
Website http://zenosense.net
Updated 07/08/2019
Zenosense, Inc. engages in developing medical devices. It includes the detection of the Methicillin-resistant Staphylococcus aureus. The firm uses Acute Myocardial Infarction, and MIDS Cardiac technologies.